Sasha Lu Austin - 30 Jan 2026 Form 3 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
VP of Finance and Controller
Signature
/s/ Shawnte Mitchell, Attorney-in-Fact
Issuer symbol
OLMA
Transactions as of
30 Jan 2026
Net transactions value
$0
Form type
3
Filing time
17 Feb 2026, 21:33:24 UTC
Next filing
17 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Austin Sasha Lu VP of Finance and Controller C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN STREET, SAN FRANCISCO /s/ Shawnte Mitchell, Attorney-in-Fact 17 Feb 2026 0002110895

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OLMA Common Stock 4,488 30 Jan 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OLMA Stock Option (Right to Buy) 30 Jan 2026 Common Stock 2,000 $2.44 Direct
holding OLMA Stock Option (Right to Buy) 30 Jan 2026 Common Stock 3,000 $2.44 Direct
holding OLMA Stock Option (Right to Buy) 30 Jan 2026 Common Stock 13,000 $2.44 Direct
holding OLMA Stock Option (Right to Buy) 30 Jan 2026 Common Stock 6,500 $4.87 Direct F1
holding OLMA Stock Option (Right to Buy) 30 Jan 2026 Common Stock 17,500 $3.49 Direct F2
holding OLMA Stock Option (Right to Buy) 30 Jan 2026 Common Stock 51,000 $15.25 Direct F3
holding OLMA Stock Option (Right to Buy) 30 Jan 2026 Common Stock 45,000 $4.37 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vested on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
F2 The shares underlying the option shall vest monthly over a four-year period commencing on April 3, 2023, with 1/48 of the shares vesting on the one-month anniversary of April 3, 2023 and the remainder of the shares vesting in equal installments on each one-month anniversary date thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
F3 25% of the shares subject to the option vested on February 1, 2025 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date
F4 25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.